Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Neutral 62.2%

Neg 0% Neu 62.2% Pos 0%

Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Target of $36.